Tiguert R - Search Results

1

ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma.

Têtu B, Tiguert R, Harel F, Fradet Y. Têtu B, et al. Among authors: tiguert r. Mod Pathol. 2005 Jan;18(1):83-9. doi: 10.1038/modpathol.3800262. Mod Pathol. 2005. PMID: 15389253 Free article.

2

New diagnostic and prognostic tools in bladder cancer.

Tiguert R, Fradet Y. Tiguert R, et al. Curr Opin Urol. 2002 May;12(3):239-43. doi: 10.1097/00042307-200205000-00011. Curr Opin Urol. 2002. PMID: 11953681 Review.

3

Safety and outcome of early catheter removal after radical retropubic prostatectomy.

Tiguert R, Rigaud J, Fradet Y. Tiguert R, et al. Urology. 2004 Mar;63(3):513-7. doi: 10.1016/j.urology.2003.10.042. Urology. 2004. PMID: 15028448 Review.

4

The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.

Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y. Mauermann J, et al. Among authors: tiguert r. Eur Urol. 2013 Jul;64(1):19-25. doi: 10.1016/j.eururo.2012.08.002. Epub 2012 Aug 10. Eur Urol. 2013. PMID: 22901983

5

Prognostic markers in muscle invasive bladder cancer.

Tiguert R, Lessard A, So A, Fradet Y. Tiguert R, et al. World J Urol. 2002 Aug;20(3):190-5. doi: 10.1007/s00345-002-0279-y. Epub 2002 Jun 7. World J Urol. 2002. PMID: 12196903 Review.

6

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.

Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y. Fradet V, et al. Among authors: tiguert r. BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25. BJU Int. 2018. PMID: 28972698 Clinical Trial.

7

Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.

Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y. Tiguert R, et al. J Urol. 2003 Aug;170(2 Pt 1):447-50. doi: 10.1097/01.ju.0000075351.51838.b3. J Urol. 2003. PMID: 12853796

8

Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.

Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y. Rigaud J, et al. Among authors: tiguert r. Prostate. 2004 Feb 15;58(3):269-76. doi: 10.1002/pros.10329. Prostate. 2004. PMID: 14743466

9

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.

Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F. Beauregard JM, et al. Among authors: tiguert r. Cancer Imaging. 2015 Mar 3;15(1):2. doi: 10.1186/s40644-015-0038-0. Cancer Imaging. 2015. PMID: 25889163 Free PMC article.

10

¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.

Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F. Otis-Chapados S, et al. Among authors: tiguert r. Can Urol Assoc J. 2021 Oct;15(10):301-307. doi: 10.5489/cuaj.7107. Can Urol Assoc J. 2021. PMID: 33750523 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page